Skip to main content
SpringerLink
Log in

Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1 B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA)

  • Original Article
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract

The biodistribution of indium-111/yttrium-88-labeled B3 monoclonal antibody, a murine IgG1k, was evaluated in non-tumor-bearing mice. B3 was conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M) or 2-(p-SCN-Bz)-1,4,7,10 tetraazacyclododecane tetra-acetic acid (2B-DOTA) and labeled with 111In at 1.4–2.4 mCi/mg and 88Y at 0.1–0.3 mCi/mg. Non-tumor-bearing nude mice were co-injected i.v. with 5–10 μCi/4–10 μg of 111In/88Y-labeled B3 conjugates and sacrificed at 6 h and daily up to 168 h post-injection. Mice injected with 111In/88Y (IB4M)-B3 showed a similar biodistribution of the two radiolabels in all tissues except the bones, where significantly higher accretion of 88Y than 111In was observed, with 2.8% ± 0.2% vs 1.3% ± 0.16% ID/g in the femur at 168 h, respectively (P<0.0001). In contrast, mice receiving the 111In/88Y-(DOTA)-B3 conjugate showed significantly higher accumulation of 111In than 88Y in most tissues, including the bones, with 2.0% ± 0.1% vs 1.2% ± 0.09% ID/g in the femur at 168 h, respectively (P<0.0001). Whereas the ratios of the areas underneath the curve (%ID × h/g) in the blood, liver, kidney and bone were 0.96, 1.12, 1.13, and 0.74 for 111In/88Y-(IB4M)-B3 and 0.84, 1.23, 1.56, and 1.31 for 111In/88Y (DOTA)-B3, respectively, ratios ≈ 1 were observed between 111In-(IB4M)-B3 and 88Y-(DOTA)-B3. In summary, while neither IB4M nor DOTA was equally stable for 111In and 88Y, the fate of 88Y- (DOTA)-B3 could be closely traced by that of 111 In-(IB4M)-B3.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Buchsbaum DJ, Langmuir VK, Wessels BW. Experimental radioimmunotherapy. Med Phys 1993; 20: 551–567.

    Google Scholar 

  2. Order SE, Sleeper AM, Stillwagon GB, Klein JL, Leichner PK. Radiolabeled antibodies: results and potential in cancer therapy. Cancer Res 1990; 50(Suppl):1011s–1013s.

    Google Scholar 

  3. Kozak RW, Atcher RW, Gansow OA, Friedman AM, Hines JJ, Waldmann TA. Bismuth-212-labeled anti-Tac monoclonal antibody: α-particle emitting radionuclides as modalities for radioimmunotherapy. Proc Natl Acad Sci USA 1986; 83: 474–478.

    Google Scholar 

  4. Deshpande SV, DeNardo SJ, Meares CF, et al. Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice. J Nucl Med 1988; 29: 217–225.

    Google Scholar 

  5. Zalutsky MR, Garg PK, Friedman HS, Bigner DD. Labeling monoclonal antibodies and F(ab')2 fragments with the α-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localization capacity. Proc Natl Acad Sci USA 1989; 86: 7149–7153.

    Google Scholar 

  6. Beaumier PL, Venkasten P, Vanderheyden J-L, et al. 186Re radioimmunotherapy of small cell lung carcinoma xenografts in nude mice. Cancer Res 1991; 51: 676–681.

    Google Scholar 

  7. Schlom J, Siler K, Milenic DE, et al. Monoclonal anti-bodybased therapy of a human tumor xenograft with a 177Iutetium-labeled immunoconjugate. Cancer Res 1991; 51: 2889–2896.

    Google Scholar 

  8. Anderson-Berg WT, Squire RA, Strand M. Specific radioimmunotherapy using 90Y labeled monoclonal antibody in erythroleukemic mice. Cancer Res 1987; 47: 1905–1912.

    Google Scholar 

  9. Sharkey RM, Kaltovich FA, Shih LB, Fand I, Govelitz G, Goldenberg DM. Radioimmunotherapy of human colonic cancer xenografts with 90Y labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res 1988; 48: 3270–3275.

    Google Scholar 

  10. Lee YC, Washburn LC, Sun TTH, et al. Radioimmunotherapy of human colorectal carcinoma xenografts using 90Y labeled monoclonal antibody C017-A prepared by two bifunctional chelate techniques. Cancer Res 1990; 50: 4546–4551.

    Google Scholar 

  11. Stewart JSW, Hird V, Snook D, et al. Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol 1990; 8: 1941–1950.

    Google Scholar 

  12. Chinol M, Hnatowich DJ. Generator-produced yttrium-90 for radioimmunotherapy. J Nucl Med 1987; 28: 1465–1470.

    Google Scholar 

  13. Wessels BW, Rogus RD. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys 1984; 11: 638–645.

    Google Scholar 

  14. Naruki Y, Carrasquillo JA, Reynolds JC, et al. Differential cellular catabolism of 111In, 90Y and 125I radiolabeled T101 anti-CD5 monoclonal antibody. Nucl Med Biol 1990; 17: 201–207.

    Google Scholar 

  15. Maecke HR, Riesen A, Ritter W. The molecular structure of indium-DTPA. J Nucl Med 1989; 30: 1235–1239.

    Google Scholar 

  16. Cotton FA, Wilkinson G. Advanced inorganic chemistry, 5th edn. New York: John Wiley, 1988.

    Google Scholar 

  17. Roselli M, Schlom J, Gansow OA, et al. Comparative biodistribution of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts. J Nucl Med 1989; 30: 672–682.

    Google Scholar 

  18. Quadri SM, Vriesendorp HM, Leichner PK, Williams JR. Evaluation of indium-111- and yttrium-90-labeled linker-immunoconjugates in nude mice and dogs. J Nucl Med 1993; 34: 938–945.

    Google Scholar 

  19. Jowsey J, Rowland RE, Marshall JH. The deposition of rare earths in bone. Radiat Res 1958; 8: 490–501.

    Google Scholar 

  20. Brechbiel MW, Gansow OA, Atcher RW, et al. Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies. Inorg Chem 1986; 25: 2772–2781.

    Google Scholar 

  21. Hnatowich DJ, Virzi F, Doherty PW. DTPA-coupled antibodies labeled with yttrium-90. J Nucl Med 1985; 26: 503–509.

    Google Scholar 

  22. Kozak RW, Raubitschek A, Mirzadeh S, et al. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and toxicity. Cancer Res 1989; 49: 2639–2644.

    Google Scholar 

  23. Sharkey RM, Motta-Hennessy C, Gansow OA, et al. Selection of a DTPA chelate conjugate for monoclonal antibody targeting to a human colonic tumor in nude mice. Int J Cancer 1990;46: 79–85.

    Google Scholar 

  24. Washburn LC, Sun TTH, Lee YCC, et al. Comparison of five bifunctional chelate techniques for 90Y labeled monoclonal antibody C017-1A. Nucl Med Biol 1991; 18: 313–321.

    Google Scholar 

  25. Cox JPL, Jankowski KJ, Kataky R, Parker D, Beeley NRA, Boyce BA, Eaton MAW, Millar K, Millican AT, Harrison A, Walker C. Synthesis of a kinetically stable yttrium-90 labeled macrocycle-antibody conjugate. J Chem Soc Chem Commun 1989;797–798.

  26. Moi MK, DeNardo SJ, Meares CF. Stable bifunctional chelates of metals used in radiotherapy. Cancer Res 1990; 50 (Suppl):789s–793s.

    Google Scholar 

  27. Deshpande SV, DeNardo SJ, Kukis DL, et al. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med 1990; 31: 473–479.

    Google Scholar 

  28. Harrison A, Walker CA, Parker D, et al. The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates. Nucl Med Biol 1991; 18: 469–476.

    Google Scholar 

  29. Meares CF, Moi MK, Diril H, et al. Macrocyclic chelates of radiometals for diagnosis and therapy. Br J Cancer 1990; 62(Suppl X): 21–26.

    Google Scholar 

  30. Snook DE, Rowlinson-Busza G, Meares CF, Epenetos AA. Indium-111-and yttrium-90-labelled macrocyclic chelating agents. In: Expenetos A (ed) Monoclonal antibodies: applications in clinical oncology, 1st edn. London: Chapman & Hall; 1991: 157–166.

    Google Scholar 

  31. Wu C, Virzi F, Hnatowich DJ. Investigation of N-linked macrocycles for 111In and 90Y labeling of proteins. Nucl Med Biol 1992; 19: 239–244.

    Google Scholar 

  32. Kosmas C, Snook D, Gooden CS, et al. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy. Cancer Res 1992; 52: 904–911.

    Google Scholar 

  33. Camera L, Kinuya S, Garmestani K, Wu C, Brechbiel MW, Pai LH, McMurry TJ, Gansow OA, Pastan I, Paik CH, Carrasquillo JA. Evaluation of the serum stability and in vivo biodistribution of the 2-(p-isothiocyanatobenzyl)-cyclohexyl-DTPA (CHX-DTPA) and other ligands for yttrium-labeling of monoclonal antibodies. J Nucl Med 1994; 35: 882–889.

    Google Scholar 

  34. McMurry TJ, Brechbiel MW, Kumar K, Gansow OA. Convenient synthesis of bifunctional tetraaza macrocycles. Bioconjugate Chem 1992; 3: 108–117.

    Google Scholar 

  35. Brechbiel MW, Gansow OA. Backbone-substituted DTPA ligands for 90Y radioimmunotherapy. Bioconjugate Chem 1991; 2: 187–194.

    Google Scholar 

  36. Pastan I, Lovelace ET, Gallo MG, Rutherford AV, Magnani JL, Willingham MC. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res 1991; 51: 3781–3787.

    Google Scholar 

  37. Mirzadeh S, Brechbiel MW, Atcher R, Gansow OA. Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin. Bioconjugate Chem 1990; 1: 59–65.

    Google Scholar 

  38. Martell AE, Smith RM. Critical stability constants. New York: Plenum Press, 1974.

    Google Scholar 

  39. Kodama M, Koike T, Mahatma AB, Kimura E. Thermodynamic and kinetic studies of lanthanide complexes of 1,4,7,10,13-pentaazacyclopentadecane-N,N′,N″,N″′,N″″-pentaac etic acid and 1,4,7,10,13,16-hexaazacyclooctadecane-N,N′,N″,N″′, N″″,N″″′-hexaacetic acid. Inorg Chem 1991; 30: 1270–1273.

    Google Scholar 

  40. Mardirossian G, Wu C, Hnatowich DJ. The stability in liver homogenates of indium-111 and yttrium-90 attached to antibody via two popular chelators. Nucl Med Biol 1993; 20: 65–74.

    Google Scholar 

  41. Shannon RD. Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenides. Acta Crystlogr A 1976; 32: 751–767.

    Google Scholar 

  42. Basolo F, Pearson RG. Mechanism of inorganic reactions. 2nd edn. New York: John Wiley, 1967.

    Google Scholar 

Download references

Author information

Author notes

  1. Luigi Camera

    Present address: Divisione di Medicina Nucleare, Istituto Nazionale Tumori “G. Pascale”, Via M. Semmola, 80131, Napoli, Italy

Authors and Affiliations

  1. Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA

    Luigi Camera, Seigo Kinuya, Chang H. Paik & Jorge A. Carrasquillo

  2. Chemistry Section, Radiation Oncology Branch, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA

    Kayhan Garmestani, Martin W. Brechbiel, Chuanchu Wu, Thomas J. McMurry & Otto A. Gansow

  3. Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA

    Lee H. Pai & Ira Pastan

Authors
  1. Luigi Camera
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seigo Kinuya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kayhan Garmestani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martin W. Brechbiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chuanchu Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lee H. Pai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Thomas J. McMurry
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Otto A. Gansow
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ira Pastan
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Chang H. Paik
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jorge A. Carrasquillo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Camera, L., Kinuya, S., Garmestani, K. et al. Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1 B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA). Eur J Nucl Med 21, 640–646 (1994). https://doi.org/10.1007/BF00285586

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00285586

Key words

Search

Navigation